Growth hormone (GH) has been linked to cardiovascular disease but the exact mechanism of this association is still unclear. We here test if the fasting levels of GH are cross-sectionally associated with carotid intima media thickness (IMT) and whether treatment with fluvastatin affects the fasting level of GH.
Methods
We examined the association between GH and IMT in 4425 individuals (aged 46–68 years) included in the baseline examination (1991–1994) of the Malmö Diet and Cancer cardiovascular cohort (MDC-CC). From that cohort we then studied 472 individuals (aged 50-70 years) who also participated (1994–1999) in the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS), a randomized, double blind, placebo-controlled, single-center clinical trial. Using multivariate linear regression models we related the change in GH-levels at 12 months compared with baseline to treatment with 40 mg fluvastatin once daily.
Results
In MDC-CC fasting values of GH exhibited a positive cross-sectional relation to the IMT at the carotid bulb independent of traditional cardiovascular risk factors (p = 0.002). In a gender-stratified analysis the correlation were significant for males (p = 0.005), but not for females (p = 0.09). Treatment with fluvastatin was associated with a minor reduction in the fasting levels of hs-GH in males (p = 0.05) and a minor rise in the same levels among females (p = 0.05).
Conclusions
We here demonstrate that higher fasting levels of GH are associated with thicker IMT in the carotid bulb in males. Treatment with fluvastatin for 12 months only had a minor, and probably not clinically relevant, effect on the fasting levels of hs-GH.
Recently we found that an increased fasting level of growth hormone (GH) is an independent predictor of cardiovascular morbidity and mortality [1]. This is somewhat surprising since GH in healthy adults is negatively associated with other predictors of cardiovascular disease (CVD) such as LDL-C, total cholesterol and triglycerides [1, 2]. GH is an anabolic stress hormone and a known regulator of lipid and glucose metabolism throughout the entire life [3]. One of the metabolic actions of GH is to increase the expression of hepatic LDL-receptors [4–6], which leads to reduced circulating levels of LDL-C. Concerning effects on glucose homeostasis, the actions of GH lead to insulin resistance and a deterioration of glucose tolerance [3, 7–9].
These two effects of GH, i.e. decreases LDL-C with negative effects on glucose homeostasis, is also seen with statins, which is one of the cornerstones in secondary and primary prevention of cardiovascular disease [10, 11]. Statins inhibit HMG-CoA-reductase, which leads to decreasing hepatic cholesterol concentration, up-regulation of LDL-receptors and eventually increased clearance of circulating low density lipoprotein cholesterol (LDL-C) [12, 13]. Similar to GH statins might have negative effects on glucose homeostasis and thus there is a small hazard of developing diabetes mellitus [14, 15]. In vitro studies also suggest that statins may lower GH gene expression [16].
Thus GH and statins share some effects on metabolism and we identified these similarities as an opportunity to further explore the previously discovered association between GH and CVD. We hypothesized that statins might affect the GH-concentration and measured the fasting levels of GH with a high-sensitivity assay (hs-GH) in a completed randomized controlled trial, originally designed to compare the effects of low-dose β-blockade and fluvastatin on the progression of carotid IMT during 36 months of treatment in subjects who had carotid plaque but no symptoms of carotid disease [17]. Since the relationship between fasting hs-GH and carotid IMT has not been previously described we also used a population based prospective cohort, the Malmö Diet and Cancer study cardiovascular cohort (MDC-CC), to study these variables. The objectives of our study were to investigate the relationship between fasting levels of GH and IMT and if treatment with fluvastatin affects the fasting level of hs-GH.
Methods
MDC-CC
The Malmö Diet and Cancer study – cardiovascular cohort (MDC-CC) is a prospective cohort examined 1991-96 with the aim to study the epidemiology of carotid artery disease. Further details about this study can be found in earlier publications [1, 18]. In brief participants underwent a physical examination and responded to a questionnaire about previous medical conditions, medications and life-style habits. Blood samples were drawn between 7.30 a.m. and 9.00 a.m. after an overnight fast and immediately stored at −80 °C. Measurement of hs-GH was made with a high-sensitivity chemiluminescence sandwich immunoassay (SphingoTec GmbH, Borgsdorf, Germany) previously described in detail [1]. The analytical assay sensitivity (mean relative light units of 20 determinations of GH free sample plus 2 S.D.; limit of detection, LOD) was 0.002 μg/L GH. The functional assay sensitivity (<20% inter assay CV; limit of quantification, LOQ) was 0.01 μg/L. GH concentration above the LOQ (0.01 μg/L) were measured with an interassay precision of typically below 10% CV. The assay was calibrated using dilutions of GH (NIBSC code 98/574, National Institute for Biological Standards and Control, Herfordshire, UK).
Carotid ultrasound
Carotid B-mode ultrasound was performed by the same 2 trained and certified sonographers at the baseline examination in the MDC-CC and in the BCAPS at baseline, 18 and 36 months as previously described [17, 19]. The same methodology was used in both studies. In brief the mean wall thickness in the right common carotid artery 1 cm proximal to the bifurcation was measured according to the leading-edge principle (IMTmeanCCA). The bifurcation area of the right common carotid artery was further scanned within a predefined window comprising 3 cm of the distal common carotid artery, the bulb, and 1 cm of the internal and external carotid artery, respectively, for the occurrence of plaques and measured as the maximum IMT at the bifurcation (IMTmaxBulb). At regular intervals (<3 weeks) during the ultrasound investigation procedure, intra- and interobserver variation analyses were performed. The mean absolute difference between two measurements in percentage with one observer measuring carotid IMT was 9.0 (standard deviation, 7.2) percent (r = 0.77) and, when using two observers, was 8.7 (standard deviation, 6.2) percent (r = 0.85). Corresponding values for the measurements of carotid stenosis assessed by Kendall’s tau were as follows: τ = 0.65 and τ = 0.72, respectively [19].
Cross-sectional analysis of IMT and hs-GH in MDC-CC
We performed a cross-sectional analysis of the relationship between hs-GH and common carotid artery (CCA) IMTmean and bifurcation (Bulb) IMTmax, in the MDC-CC. In multivariate regression models with IMTmeanCCA as the dependent variable and the standardized value of the natural logarithm of hs-GH as independent we analyzed 4425 subjects (aged 46–68 years; 58% women) with values on both hs-GH and IMTmeanCCA. One model was adjusted for age and sex, and a second model was in addition adjusted for a set of traditional cardiovascular risk factors: smoking, systolic blood pressure, anti-hypertensive medication, body mass index (BMI), LDL-C, high density lipoprotein cholesterol (HDL-C) and diabetes mellitus. In females an additional analysis was performed adjusted for menopausal status (pre, peri, post) and use of hormone replacement therapy.
The same approach was used in the analysis of hs-GH and IMTmaxBulb, where 3397 subjects (aged 46–68 years, 58% women) had complete data.
BCAPS
The β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) was a randomized, double blind, placebo-controlled, single-center clinical trial that took place between 1994 and 1999. A detailed description of BCAPS can be found in the original paper [17], following here is a brief summary.
The original study population consisted of 361 men and 432 women (total n = 793) 49 to 70 years of age recruited from the MDC-CC (Fig. 1). All participants included in BCAPS had carotid plaque but no symptoms of carotid artery disease. Exclusion criteria were: myocardial infarction, angina pectoris or stroke within the previous 3 months; previous surgery in the right carotid artery; regular use of β-blockers or statins; blood pressure > 160 (systolic) or >95 (diastolic) mm Hg; total cholesterol >8.0 mmol/l; hyperglycemia suspected to require insulin treatment; and conditions that in the view of the investigator made the participant unsuitable for the trial.
Fig. 1
Flow chart of the recruitment to MDC-CC and BCAPS. Overview of the recruitment to the study populations from the Malmö Diet and Cancer study. Figure shows the relation between the studies and the times and reasons for exclusion. Abbreviations: MDCS – Malmö Diet and Cancer study
Randomization
The participants were randomly assigned to 1 of 4 drug combination groups according to a factorial design (Fig. 2): placebo/placebo, metoprolol CR/XL (25 mg once daily)/placebo, fluvastatin (40 mg once daily)/placebo or metoprolol CR/XL (25 mg once daily)/fluvastatin (40 mg once daily).
Fig. 2
Randomization groups in BCAPS. Schematic drawing of the randomization groups in BCAPS
Study length and blood sampling in BCAPS
The treatment period was 36 months. Blood samples were drawn after an overnight fast between 7.30 a.m. and 10.00 a.m. at baseline and at 12, 24 and 36 months. Levels of hs-GH were measured in stored fasting plasma samples, which were frozen immediately to −20 °C at the different examinations. The same high-sensitivity immunoassay used for measuring hs-GH in MDC-CC was used to measure hs-GH in BCAPS. A number of the samples stored in the freezer were missing or had insufficient plasma for the analysis of hs-GH. Subjects in which either the baseline-value of hs-GH (n = 199) or the 12-month value of hs-GH (n = 167) was missing were excluded from further analysis in BCAPS. After this adjustment the study consisted of 472 individuals (aged 50-70 years; 63% women).
Statistical analyses in BCAPS
The four original randomization groups are in some analyses pooled into fluvastatin vs non-fluvastatin (i.e placebo) or metoprolol vs non-metoprolol (Fig. 2). Since fasting hs-GH is known to differ between men and women all models were performed separate for men and women as well as combined.
To investigate if fasting hs-GH was affected by treatment with fluvastatin or metoprolol we performed multivariate linear regression analysis with the standardized value of the natural logarithm of ΔGH (baseline value subtracted from 12 month value) as the dependent variable and the treatment group as an independent variable and adjusted for sex, age, and the natural logarithm of the fasting level of hs-GH at baseline. Separate models were performed with each of the treatment groups vs the original or pooled placebo groups depending on model. As a sensitivity analysis another model was in addition adjusted for LDL-C at baseline and at 12 months.
We then analyzed if the baseline value of, or 12-month change in, hs-GH affects the treatment effect of fluvastatin or metoprolol on the IMT at 36 months in a series of multivariate regression models. A small number of individuals did not complete the ultrasound examination at 36 months and in these individuals the latest IMT-values (i.e. at 18 months) are used. The analyses were adjusted for time between IMT-measurements, IMT at baseline, age, sex (if not already gender separated) and the natural logarithm of the fasting level of hs-GH at baseline.
The initial model analyzed IMT at 36 months as the dependent variable and hs-GH at baseline and treatment with fluvastatin or metoprolol as independent variables. If the main effects (GH and medication) were significant we would then perform an interaction analysis.
The second model analyzed IMT at 36 months as outcome, but with ΔGH (0–12 months) as the independent variable together with treatment with fluvastatin or metoprolol.
All analyses were performed in SPSS (version 22.0.0, SPSS Inc., Chicago, Ill). A 2-sided P-value of less than 0.05 was considered statistically significant.
Results
Association between carotid IMT and hs-GH in MDC-CC
Baseline characteristics of the MDC-CC have been published previously [1]. In the cross-sectional linear regression model of 3397 (1957 females, 58%) individuals, the fasting levels of hs-GH exhibited a significant positive correlation with IMTmaxBulb (P = 0.003) (Table 1). In a sex-stratified analysis this positive association was significant in males (P = 0.003) but not among females (P = 0.18). The associations among males and the total cohort remained strong when adjusting for traditional cardiovascular risk factors (P = 0.002 and P = 0.005 respectively).
Table 1
Cross-sectional linear regression in the MDC-CC with IMT at baseline as dependent variable and hs-GH as independent. One crude model adjusted for sex and age and one model in addition adjusted for traditional cardiovascular risk factorsa
Dependent
Gender
Modela
Betab
95%CI
P
IMTmax Bulb
ALL
Crude
0.060
0.020 to 0.099
0.003
(n = 3397)
Adjusted
0.066
0.025 to 0.106
0.002
MALE
Crude
0.075
0.025 to 0.125
0.003
(n = 1440)
Adjusted
0.074
0.022 to 0.125
0.005
FEMALE
Crude
0.029
−0.014 to 0.072
0.18
(n = 1957)
Adjusted
0.038
−0.006 to 0.083
0.09
IMTmeanCCA
ALL
Crude
−0.012
−0.046 to 0.021
0.48
(n = 4425)
Adjusted
0.017
−0.017 to 0.052
0.32
MALE
Crude
0.011
−0.033 to 0.054
0.63
(n = 1767)
Adjusted
0.024
−0.020 to 0.068
0.28
FEMALE
Crude
−0.027
−0.063 to 0.009
0.15
(n = 2658)
Adjusted
0.001
−0.036 to 0.038
0.97
aCrude models adjusted for sex and age. Adjusted models adjusted for: sex, age, systolic blood pressure, antihypertensive medication, diabetes mellitus, current smoking, BMI, LDL-C and HDL-C
bThe β coefficients are expressed as the increment of standardized values of the natural logarithm of IMT per 1 increment of standardized values of the natural logarithm of hs-GH
No significant associations were found between the fasting levels of hs-GH and IMTmeanCCA neither crude nor adjusted in the 4425 individuals (2658 females, 60%) that were available in this analysis.
To rule out that the difference in the results with the association with hs-GH between the two IMT measurements were not due to a selection bias, we also analyzed IMTmeanCCA in the 3397 individuals mentioned previously. IMTmeanCCA was available in 3390 of these and did not show any significant correlation with hs-GH in crude and adjusted models (data not shown).
As sensitivity analyses the adjusted regression models were additionally adjusted for variables that could affect GH. The relation between hs-GH and IMT in women remained non-significant after additional adjustment for menopausal status and hormone replacement therapy. Additional adjustment for waist hip ratio (WHR) marginally improved all models. The results in IMTmeanCCA were however still non-significant, but adjustment for WHR in IMTmaxBulb made fasting hs-GH significantly associated with IMTmaxBulb in females (Beta, 0.044; 95%CI, 0.000-0.089; P = 0.05) and the association remained strong among all (Beta, 0.068; 95%CI, 0.027–0.108; P = 0.001) and males (Beta, 0.074; 95%CI, 0.022–0.125; P = 0.005).
BCAPS
Baseline characteristics of the 472 individuals in the BCAPS study population were similar in the different treatment groups and are shown in Table 2. The females in all groups had higher values of hs-GH at baseline compared with males. In the group of subjects in which hs-GH could not be measured due to missing samples at either baseline or 12 months there were more males than females (Additional file 1: Table S1). The median values for IMTmeanCCA and IMTmaxBulb were higher in the males excluded from the study, while the anthropometrics were similar to the study population in both genders. The missing samples were evenly distributed over the different treatment groups but the male/female ratio was marginally different in two of the four treatment groups (Table 2).
Table 2
Baseline clinical characteristics of the study population in BCAPS
Variable
Placebo/Placebo
Metoprolol/Placebo
Fluvastatin/Metoprolol
Fluvastatin/Placebo
Number of participants
117
118
117
120
Female (%)
78 (66.7)
78 (66.1)
70 (59.8)
72 (60.0)
Age, mean (SD), years
61.5 (5.7)
60.3 (5.6)
62.3 (5.0)
61.8 (5.4)
Height, mean (SD), cm
168 (10)
167 (8)
169 (8)
169 (9)
Body Mass Index, Mean (SD), kg/m2
25.5 (3.6)
25.5 (3.6)
25.1 (2.7)
25.7 (3.7)
LDL-C, mean (SD), mmol/L
4.07 (0.86)
4.18 (0.92)
4.15 (0.88)
4.16 (0.82)
HDL-C, mean (SD), mmol/L
1.48 (0.40)
1.39 (0.37)
1.41 (0.35)
1.37 (0.35)
IMTmean CCA, median (IQR)
0.88 (0.78-0.96)
0.88 (0.77-0.99)
0.86 (0.79-0.98)
0.86 (0.78-0.97)
IMTmax Bulb median (IQR)
1.74 (1.46-2.09)
1.77 (1.49-2.24)
1.84 (1.52-2.29)
1.81 (1.55-2.17)
Growth Hormone - males, median (IQR), μg/L
0.28 (0.06-0.84)
0.15 (0.06-0.35)
0.15 (0.06-0.97)
0.18 (0.08-0.57)
Growth Hormone - females, median (IQR), μg/L
1.49 (0.58-3.14)
1.52 (0.49-2.64)
1.16 (0.53-2.32)
1.53 (0.68-2.74)
Missing values in IMTmaxbulb: placebo/placebo, n = 3; metoprolol/placebo n = 3; Fluvastatin/Metoprolol, n = 5; fluvastatin/placebo, n = 8
Missing values in HDL-C and LDL-C: placebo/placebo, n = 1; metoprolol/fluvastatin n = 1
hs-GH and treatment with fluvastatin
Unadjusted values in the treatment groups on hs-GH and IMT at follow-up can be found in Table 3 and Fig. 3. In linear regression models the change in levels of hs-GH at 12 months compared with baseline (ΔGH) were related against the different treatment groups (Table 4). In males treatment with fluvastatin/metoprolol was associated with a reduction of hs-GH over 12 months compared with placebo (P = 0.03). The levels of hs-GH were also reduced over 12 months with fluvastatin treatment compared with placebo in males (P = 0.05). On the contrary, among females both treatment with fluvastatin/metoprolol and fluvastatin was associated with an increase in the level of hs-GH over 12 months (P = 0.02 and P = 0.05 respectively) when compared with placebo.
Table 3
Characteristics of the BCAPS population after medical treatment
Variable
Placebo/Placebo
Metoprolol/Placebo
Fluvastatin/Metoprolol
Fluvastatin/Placebo
12 months
LDL-C, mean (SD), mmol/L
4.01 (0.82)
4.17 (0.87)
3.21 (0.85)
3.27 (0.74)
Growth Hormone - males, median (IQR), μg/L
0.16 (0.08-0.59)
0.17 (0.04-0.57)
0.21 (0.06-0.95)
0.12 (0.07-0.44)
Growth Hormone - females, median (IQR), μg/L
0.82 (0.40-1.99)
0.93 (0.41-2.20)
1.25 (0.53-2.50)
0.88 (0.41-2.01)
36 months
IMTmean CCA, median (IQR)
0.91 (0.82-1.04)
0.90 (0.83-1.02)
0.87 (0.78-0.98)
0.87 (0.77-0.99)
IMTmax Bulb, median (IQR)
1.98 (1.71-2.35)
1.89 (1.60-2.43)
1.99 (1.60-2.44)
2.02 (1.68-2.30)
Missing values in IMTmean CCA: placebo/placebo, n = 4; metoprolol/placebo n = 1; fluvastatin/placebo, n = 1
Missing values in IMTmax Bulb: placebo/placebo, n = 6; metoprolol/placebo n = 4; Fluvastatin/Metoprolol, n = 6; fluvastatin/placebo, n = 8
Missing values in LDL-C: placebo/placebo, n = 2; metoprolol/placebo n = 6; Fluvastatin/Metoprolol, n = 1; fluvastatin/placebo, n = 3
Fig. 3
Boxplots of fasting levels of hs-GH in the different randomization groups at baseline and after 1 year of treatment
Table 4
Multivariate linear regression models of the effect of different treatment regimes on the change in fasting levels of hs-GH over 12 months in BCAPS
Sex
Modela
Treatment group
N (med/placebo)
Bb
95%CI
P
All
Original
Metoprolol-Placebo
118/117
−0.09
−0.35 to 0.17
0.48
Fluvastatin-Metoprolol
117/117
0.10
−0.13 to 0.33
0.38
Fluvastatin-Placebo
120/117
−0.04
−0.24 to 0.17
0.72
Pooled
Fluvastatin
237/235
0.08
−0.09 to 0.24
0.24
Pooled
Metoprolol
235/237
0.02
−0.14 to 0.19
0.80
Male
Original
Metoprolol-Placebo
40/39
−0.17
−0.55 to 0.21
0.38
Fluvastatin-Metoprolol
47/39
−0.53
−1.02 to −0.04
0.03
Fluvastatin-Placebo
48/39
−0.15
−0.42 to 0.11
0.26
Pooled
Fluvastatin
95/79
−0.27
−0.54 to 0.00
0.05
Pooled
Metoprolol
87/87
−0.25
−0.52 to 0.02
0.07
Female
Original
Metoprolol-Placebo
78/78
−0.07
−0.38 to 0.25
0.68
Fluvastatin-Metoprolol
70/78
0.32
0.06 to 0.58
0.02
Fluvastatin-Placebo
72/78
0.03
−0.23 to 0.28
0.83
Pooled
Fluvastatin
142/156
0.20
0.00 to 0.41
0.05
Pooled
Metoprolol
148/150
0.10
−0.10 to 0.31
0.33
Models adjusted for: age and standardized values of natural logarithm of GH at baseline. In addition adjusted for sex in the analysis for all
aThree different models are performed: in “original” the different treatment groups are each one compared with placebo. In “pooled” the individuals receiving fluvastatin are pooled and compared with individuals not receiving fluvastatin and vice versa with metoprolol.
bB coefficients are expressed as the SD increment of the natural logarithm of ΔGH (12 months – baseline) with treatment of the medicine in question as compared with placebo.
When analyses were in addition adjusted for levels of LDL-C at baseline and at 12 months, the results were attenuated so that none of the treatments were associated with the fasting levels of hs-GH (Additional file 1: Table S2).
hs-GH and effect of medical therapy on the IMT outcome in BCAPS
Multivariate regression models including hs-GH at baseline and the pooled randomization groups with IMT outcome at 36 months as dependent variable were performed to evaluate if hs-GH at baseline affected the outcome of medical therapy on the IMT. Adjusted for treatment with fluvastatin, the baseline fasting value of hs-GH did not show any associations with neither IMTmeanCCA nor IMTmaxBulb outcome in the whole cohort (P = 0.75 and P = 0.54 respectively), in males (P = 0.95 and P = 0.76) and in females (P = 0.54 and P = 0.36). When instead adjusting for treatment with metoprolol the correlations between the fasting value of hs-GH and IMTmeanCCA or IMTmaxBulb outcome were still non-significant in the whole cohort (P = 0.74 and P = 0.48 respectively), in males (P = 0.96 and P = 0.79) and in females (P = 0.59 and P = 0.28).
In similar multivariate regression models as in the previous paragraph we investigated if ΔGH (12-0 months) was associated with IMT outcome at 36 months, to evaluate if change in hs-GH affected the outcome of medical therapy on the IMT. ΔGH was not associated with neither IMTmeanCCA nor IMTmaxBulb outcome when adjusting for treatment with fluvastatin in the whole cohort (P = 0.74 and P = 0.18 respectively), in males (P = 0.98 and P = 0.39) and in females (P = 0.67 and P = 0.48). When instead adjusting for treatment with metoprolol the correlations between ΔGH and IMTmeanCCA or IMTmaxBulb outcome were still non-significant in the whole cohort (P = 0.64 and P = 0.16 respectively), in males (P = 0.60 and P = 0.33) and in females (P = 0.51 and P = 0.34).
Since the correlations between GH or change in GH and IMT outcome at 36 months in BCAPS were non-significant, no further interaction analyses between hs-GH and the different medical treatments were performed.
Discussion
This is the first study examining whether the fasting levels of hs-GH are associated with carotid IMT in the general population and if treatment with fluvastatin affects the fasting values of hs-GH. Higher fasting levels of hs-GH were associated with an increased IMT in the carotid bulb in males independently of traditional cardiovascular risk factors. The fasting levels of hs-GH were only to a minor, and probably clinically non-relevant, degree affected by treatment with fluvastatin.
Fasting hs-GH and IMT
Previous results have shown that higher fasting values of hs-GH are associated with increased cardiovascular morbidity and mortality, especially in males [1, 20]. The positive association between hs-GH and the IMT at the carotid bulb in the current study is in harmony with these former results and the relation is once again stronger in the male part of the population. As atherosclerosis primarily presents in the bulb region, the IMT in the carotid bulb is a good measure of atherosclerosis and has been shown to be useful in risk prediction [21]. The IMT in the common carotid artery is more associated with hypertension and stroke [21], i.e. vascular aging and did not show any association with fasting hs-GH in our study. This suggests that the previously described link between fasting levels of hs-GH and cardiovascular disease could be mediated by atherosclerosis, at least in males.
Several studies have been made to elucidate the connection between IMT and GH in the more extreme forms of GH deficiency or GH excess (acromegaly). Results are often conflicting and comparisons between the studies are difficult since different measurements of IMT often are used. In line with our results, a study on acromegalic patients showed increased IMT (composite variable of bulb + CCA) in patients when compared with controls [22]. At the other end, GH-deficient patients have been shown to have an elevated mean bulb IMT when compared with controls, but not when compared with BMI-matched controls [23, 24]. Bulow et. al investigated the bulb IMT in female GH-deficient patients and did not find any significant difference when compared with healthy controls [25]. GH replacement therapy has in some studies shown beneficial effects on the bulb IMT in individuals with adult-onset GHD [23, 26, 27], but negative effects in congenital GHD [28]. Thus, data from GHD-patients are conflicting and if anything indicates a negative association between GH and bulb IMT, but data from acromegaly patients support our finding with the association being positive. It is however uncertain to what extent data from these previous studies can be extrapolated to a general healthy population, such as ours.
In our previous study, where we found that the fasting levels of hs-GH independently predicted cardiovascular disease and death, we observed that this association was to a larger extent driven by the male part of the population [1]. In the current study we observed similar gender differences, hs-GH was associated with thickness of the carotid bulb only in men, which is not surprising given our previous results. One explanation of this difference might be that women have higher basal levels and a more irregular secretion of GH than men [1, 29, 30]. This probably makes a single hs-GH value a more uncertain measure in women, even if drawn fasting in the morning.
Effect of fluvastatin treatment on fasting hs-GH
In males, treatment with metoprolol/fluvastatin compared with placebo/placebo was associated with a reduction of hs-GH over 12 months of treatment independently of baseline level of hs-GH. The effect was however quite small and the change in absolute values were minor. It should also be noted that the change of hs-GH over 12 months in the fluvastatin/placebo-group was not significantly different when compared with the placebo/placebo group. The same applies to the female part of the cohort where treatment with metoprolol/fluvastatin and fluvastatin (pooled) was associated with elevation of hs-GH over 12 months. The elevation of hs-GH among women was not absolute, but relative as the placebo/placebo group had the greatest reduction in levels of fasting hs-GH (Fig. 3).
The pharmacokinetics of fluvastatin in men and women are not known to differ substantially [31]. Two recent studies investigating gender differences on statin treatment, with regards to its cholesterol lowering and cardio-protective effects, did not find any large differences that could explain our results [32, 33]. Possibly the irregular secretion of hs-GH in females (see previous section) could have influenced the data.
When adjusting for LDL-C at baseline and at 12 months the associations between treatment and fasting hs-GH were no longer significant in any gender. Taken together, our data indicate that any effects of fluvastatin or metoprolol on the fasting levels of hs-GH are small and probably not clinically relevant.
Strengths and limitations
There are some limitations to our study. First, the original randomized clinical trial was neither designed nor purposed to analyze the effect on the fasting level of hs-GH. About 40% of the participants had insufficient amount of plasma stored in the freezer from either the examination at baseline or at 12 months and we were forced to exclude them to keep an intact study population. This probably makes the fluvastatin-part of the study a bit underpowered. A larger part of the missing samples were drawn from male participants and both measures of the IMT in these males were higher than the IMT of the males in the study. A selection bias cannot be ruled out, but we do not have a plausible theory of the mechanism of this selection. The missing samples made the male/female ratio different in the treatment groups, but as all analyses were performed separate for men and women, this should not be an issue.
We chose to focus our analysis on the change in hs-GH after 12 months of treatment. The reasons for this are many. First, we hypothesized that any change in the levels of hs-GH would be visible at this time and that any potential effect of the medicine on hs-GH would not increase with a longer treatment period. Second, the data at 12 months is probably the most “clean” data, compliance tend to be highest in the beginning of a study. Third, some subjects were during follow-up prescribed open-label lipid lowering therapy, antihypertensive medication etc. [17], which also might affect the data more at later time points. Finally, there were missing plasma samples at all time points and if we would extend our analysis to them we would have been forced to exclude additional individuals and thus further diminishing our study population.
The pulsatile mode of secretion of hs-GH is as previously discussed [1] a limitation since the blood samples might be taken during a peak in a few individuals. The samples were drawn in the morning when peaks are scarce [34–36] and this potential irregularity in the measurements would, if anything, dilute an association. A single fasting value of hs-GH is not a standard clinical test, the correlation between fasting GH and 24-h GH secretion is strong, but with large variability [37]. However as we have previously shown on a population basis [1], a single fasting value of hs-GH strongly and independently predicts cardiovascular disease and death, which calls for further research on the subject. Apart from the pulsatile GH release, it should be emphasized that there are many potential external influences on fasting GH such as emotional or physical stress and that this may dilute any true relationship between hs-GH and carotid IMT.
Conclusions
In conclusion we here demonstrate that the fasting levels of hs-GH are associated with the IMT at the carotid bulb in males and suggest atherosclerosis as the likely cause of the previously described association between hs-GH and hard cardiovascular endpoints. Treatment with fluvastatin was associated with only small changes, which differed between the genders, in the fasting levels of hs-GH. This indicates that any effect of fluvastatin on fasting hs-GH is small and probably not clinically relevant.
Abbreviations
BCAPS:
The β-blocker cholesterol-lowering asymptomatic plaque study
GH:
Growth hormone
hs-GH:
High sensitivity growth hormone
IMT:
Intima media thickness
IMTmaxBulb:
Maximum Intima Media Thickness in the carotid bulb
IMTmeanCCA:
Mean Intima Media Thickness in the common carotid artery
MDC-CC:
Malmö diet and cancer study – cardiovascular cohort
Declarations
Acknowledgements
This study would not have been possible to perform without help from the many skilled co-workers at the clinical research unit (KFE) in Malmö.
Funding
Funding was obtained from the European Research Council (StG-282,255); Swedish Heart and Lung Foundation; Swedish Research Council; Novo Nordisk Foundation; Skåne University Hospital donation funds; Medical Faculty, Lund University; governmental funding of clinical research within the National Health Services; the Albert Påhlsson Research Foundation; Region Skåne; the King Gustaf V and Queen Victoria Foundation; the Marianne and Marcus Wallenberg Foundation; and Esther Olsson foundation II and Anna Jönsson foundation.
Availability of data and materials
Due to ethical and legal restrictions related to the Swedish Biobanks in Medical Care Act (2002:297) and the Personal Data Act (1998:204), data are not stored in an online repository, but is available upon request from the data access group of Malmö Diet and Cancer study by contacting Anders Dahlin (anders.dahlin@med.lu.se).
Authors’ contributions
Authors EH and OM had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: OM, EH, AB, BH, GE. Acquisition of data: OM, MP, BH, GE, AB, GÖ. Analysis and interpretation of data: EH, OM, PA, BH, GE, MP, AB, GÖ, JS, MR. Drafting of the manuscript: EH, OM. Critical revision of the manuscript for important intellectual content: EH, OM, PA, BH, GE, MP, AB, GÖ, JS, MR. Statistical analysis: EH, PA, OM. Obtained funding: OM, BH, AB, EH. Administrative, technical, or material support: OM, EH, BH, AB, JS, GÖ. Study supervision: OM, BH, GE, AB. All authors read and approved the final manuscript.
Competing interests
GE is a former employee of AstraZeneca. AB is the president/CEO of Sphingotec GmbH, which holds the patent rights for use of the high-sensitivity growth hormone assay used in this paper. JS is the Head of Research & Development at the same company.
The original BCAPS-study was funded by Astra Zeneca. Astra Zeneca neither participated in nor funded the current study.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All participants in MDC-CC and BCAPS provided written consent and the studies were approved by The Ethics Committee of Lund University.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
(1)
Department of Clinical Sciences, Lund University
(2)
Department of Internal Medicine, Skåne University Hospital
(3)
SphingoTec GmbH
(4)
Waltraut Bergmann Foundation
(5)
Department of Internal Medicine, SUS, Skåne University Hospital
References
Hallengren E, Almgren P, Engstrom G, Hedblad B, Persson M, Suhr J, Bergmann A, Melander O. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmo diet and cancer study. J Am Coll Cardiol. 2014;64(14):1452–60.View ArticlePubMedPubMed CentralGoogle Scholar
Vahl N, Klausen I, Christiansen JS, Jorgensen JO. Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin Endocrinol. 1999;51(3):309–16.View ArticleGoogle Scholar
Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–77.View ArticlePubMedGoogle Scholar
Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci U S A. 1992;89(15):6983–7.View ArticlePubMedPubMed CentralGoogle Scholar
Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I. Arterioscler Thromb Vasc Biol. 1995;15(7):847–9.View ArticlePubMedGoogle Scholar
Rudling M, Olivecrona H, Eggertsen G, Angelin B. Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor I. J Clin Invest. 1996;97(2):292–9.View ArticlePubMedPubMed CentralGoogle Scholar
Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000;133(2):111–22.View ArticlePubMedGoogle Scholar
Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89(5):2192–9.View ArticlePubMedGoogle Scholar
Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab. 2003;88(4):1455–63.View ArticlePubMedGoogle Scholar
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.View ArticlePubMedGoogle Scholar
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012;223(1):1–68.View ArticlePubMedGoogle Scholar
Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983;80(13):4124–8.View ArticlePubMedPubMed CentralGoogle Scholar
Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N, The Diabetes Subpanel of the National Lipid Association Expert P. An assessment by the Statin diabetes safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17–29.View ArticlePubMedGoogle Scholar
Lasa M, Chiloeches A, Garcia N, Montes A, Toro MJ. Lovastatin decreases prolactin and growth hormone gene expression in GH4C1 cells through a cAMP dependent mechanism. Mol Cell Endocrinol. 1997;130(1-2):93–100.View ArticlePubMedGoogle Scholar
Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation. 2001;103(13):1721–6.View ArticlePubMedGoogle Scholar
Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo diet and cancer study. Design and feasibility. J Intern Med. 1993;233(1):45–51.View ArticlePubMedGoogle Scholar
Rosvall M, Ostergren PO, Hedblad B, Isacsson SO, Janzon L, Berglund G. Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmo diet and cancer study. Am J Epidemiol. 2000;152(4):334–46.View ArticlePubMedGoogle Scholar
Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ (Clinical research ed). 1998;316(7138):1132–3.View ArticleGoogle Scholar
Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014;7(10):1025–38.View ArticlePubMedGoogle Scholar
Ozkan C, Altinova AE, Cerit ET, Yayla C, Sahinarslan A, Sahin D, Dincel AS, Toruner FB, Akturk M, Arslan M. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary. 2015;18(5):621–9.View ArticlePubMedGoogle Scholar
Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999;84(2):453–7.PubMedGoogle Scholar
Leonsson M, Hulthe J, Oscarsson J, Johannsson G, Wendelhag I, Wikstrand J, Bengtsson BA. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol. 2002;57(6):751–9.View ArticleGoogle Scholar
Bulow B, Hagmar L, Eskilsson J, Erfurth EM. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab. 2000;85(2):574–84.PubMedGoogle Scholar
Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, Savanelli MC, Lombardi G. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008;93(9):3416–24.View ArticlePubMedGoogle Scholar
Cenci MC, Conceicao FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metab Clin Exp. 2008;57(1):121–9.View ArticlePubMedGoogle Scholar
Araujo VP, Aguiar-Oliveira MH, Oliveira JL, Rocha HM, Oliveira CR, Rodrigues TM, Nunes MA, Britto IM, Ximenes R, Barreto-Filho JA, et al. Arrest of atherosclerosis progression after interruption of GH replacement in adults with congenital isolated GH deficiency. Eur J Endocrinol/Eur Fed Endocr Soc. 2012;166(6):977–82.View ArticleGoogle Scholar
Hindmarsh PC, Dennison E, Pincus SM, Cooper C, Fall CH, Matthews DR, Pringle PJ, Brook CG. A sexually dimorphic pattern of growth hormone secretion in the elderly. J Clin Endocrinol Metab. 1999;84(8):2679–85.View ArticlePubMedGoogle Scholar
Veldhuis JD, Roelfsema F, Keenan DM, Pincus S. Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults. J Clin Endocrinol Metab. 2011;96(1):115–21.View ArticlePubMedGoogle Scholar
Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, Wenger NK, Waters DD. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Am J Cardiol. 2015;115(4):447–53.View ArticlePubMedGoogle Scholar
Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, et al. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014;7(10):1013–22.View ArticlePubMedGoogle Scholar
Saini S, Hindmarsh PC, Matthews DR, Pringle PJ, Jones J, Preece MA, Brook CG. Reproducibility of 24-hour serum growth hormone profiles in man. Clin Endocrinol. 1991;34(6):455–62.View ArticleGoogle Scholar
Surya S, Symons K, Rothman E, Barkan AL. Complex rhythmicity of growth hormone secretion in humans. Pituitary. 2006;9(2):121–5.View ArticlePubMedGoogle Scholar
Jaffe CA, Ocampo-Lim B, Guo W, Krueger K, Sugahara I, DeMott-Friberg R, Bermann M, Barkan AL. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest. 1998;102(1):153–64.View ArticlePubMedPubMed CentralGoogle Scholar
Roelfsema F, Veldhuis JD. Growth hormone dynamics in healthy adults are related to age and sex and strongly dependent on body mass index. Neuroendocrinology. 2016;103(3-4):335–44.View ArticlePubMedGoogle Scholar
